Investor Presentaiton
5
Growth & Launch Products Revenue Grew +19% at CER in FY22 H1
(M)
GI
MM
RARE DISEASES
0
PLASMA-DERIVED
THERAPIES (PDT)
IMMUNOLOGY
ONCOLOGY
NEUROSCIENCE
Takeda
OTHER
Entyvio
vedolizumab
TAKHZYRO
(lanadelumab-flyo) injection
+31%
+17%
GROWTH
&
LAUNCH
PRODUCTS
ALOFISEL
+33%
HyQvia
GAMMAGARDLIQUID
[Immune Globulin
Intravenous (Human)] 10%
Human Normal Immunoglobulin (0%)
Recombinant Human Hyaluronidase
Cuvitru
Immure Globulin Subcutaneous Human 20%
IMMUNOGLOBULIN
+17%
LIVTENCITY™
tablets
(maribavir) 200
New Launch
Flexbumin
(Human Albumin)
HUMANALBUMIN
ALBUMIN
+8%
ALUNBRIG
BRIGATINIB
30 mg TABLETS
+41%
EXKIVITY
mobocertinib
40 mg capsules
New Launch
ウイルスワクチン
COVID-19 Vaccine
spikevax
Suspension for
Intramuscular Injection
(JP)
ヌバキソビッド筋注
NuvaxovidⓇ
(JP)
Total FY2022 H1 Revenue 759.8B (USD 5.3B)¹ (+19% growth at CER)
Ninlaro IclusigⓇ
Adcetris (ex-N. America)
Leuprorelin
Advate/AdynoviⓇ
OTHER KEY
PRODUCTS
Takecab/VocintiⓇ
Gattex/RevestiveⓇ
VonvendiⓇ Elaprase®
VprivⓇ ReplagalⓇ(EU,JP)
GlassiaⓇ
AralastⓇ
VyvanseⓇ
Trintellix (US,JP)
AzilvaⓇ (JP)
Zejula (UP) CabometyxⓇ (JP)
All growth rates indicate FY2022 H1 revenue growth at CER
1. Convenience translation at an exchange rate of 1USD = 144.71 JPY, the Noon Buying Rate certified by the Federal Reserve Bank of New York on September 30, 2022.View entire presentation